Product NDC: | 49702-221 |
Proprietary Name: | ZIAGEN |
Non Proprietary Name: | abacavir sulfate |
Active Ingredient(s): | 300 mg/1 & nbsp; abacavir sulfate |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, FILM COATED |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 49702-221 |
Labeler Name: | ViiV Healthcare Company |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA020977 |
Marketing Category: | NDA |
Start Marketing Date: | 19981229 |
Package NDC: | 49702-221-18 |
Package Description: | 60 TABLET, FILM COATED in 1 BOTTLE (49702-221-18) |
NDC Code | 49702-221-18 |
Proprietary Name | ZIAGEN |
Package Description | 60 TABLET, FILM COATED in 1 BOTTLE (49702-221-18) |
Product NDC | 49702-221 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | abacavir sulfate |
Dosage Form Name | TABLET, FILM COATED |
Route Name | ORAL |
Start Marketing Date | 19981229 |
Marketing Category Name | NDA |
Labeler Name | ViiV Healthcare Company |
Substance Name | ABACAVIR SULFATE |
Strength Number | 300 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |